Dashboard
Lantheus Holdings, Inc.
LNTHNASDAQFor informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Universal block
Live market data + trailing fundamentals.
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Nov 19Ownership changeSEC
Form 4 filing reporting change in beneficial ownership of securities.
- Nov 10OtherSEC
8-K filing (item 8.01) on November 10, 2026.
- Nov 5Financial resultsSEC
Lantheus Holdings filed 8-K with items 2.02 and 9.01 disclosing results of operations.
- Oct 22OtherSEC
Lantheus Holdings filed Form 8-K item 8.01 other events on 2026-10-22.
- Oct 14OtherSEC
Lantheus Holdings filed 8-K item 5.07 reporting results of matters submitted to a shareholder vote.
- Oct 2OtherSEC
Lantheus Holdings filed Form 8-K item 8.01 on 2026-10-02.
- Sep 21OtherSEC
8-K filed under item 8.01 (other events).
- Sep 8Ownership changeSEC
Form 4 filing reporting change in beneficial ownership of securities by an insider.
- Sep 8M&ASEC
Filed DEFM14A definitive proxy statement for merger or acquisition.
- Sep 4Ownership changeSEC
Form 4 filing reporting change in beneficial ownership of securities.
- Sep 3Ownership changeSEC
Form 4 filing: statement of changes in beneficial ownership of securities.
- Sep 2Ownership changeSEC
Form 4 filing: statement of changes in beneficial ownership of securities.
- Sep 2Ownership changeSEC
Form 4 filing reporting change in beneficial ownership of securities.
- Aug 26M&ASEC
PREM14A preliminary proxy statement filed for merger or acquisition.
- Aug 19Ownership changeSEC
Form 4 filing: statement of changes in beneficial ownership of securities.
- Aug 19Ownership changeSEC
Form 4 filing: statement of changes in beneficial ownership of securities.
- Aug 6Financial resultsSEC
Lantheus Holdings files 8-K (items 2.02, 9.01) disclosing results of operations and financial condition.
- Aug 4LeadershipSEC
8-K reports entry into material definitive agreement (item 1.01) and officer/director changes (item 5.02).
- Aug 3OtherSEC
Lantheus Holdings files 8-K covering items 7.01 (Reg FD), 8.01 (other events), and 9.01 (exhibits).
- Jul 22RegulatoryFDA
FDA supplemental submission (SUPPL-41) action for NEURACEQ under NDA204677.
Not financial advice — research and opinion only. Disclosures